Fig. 1.

Company’s model structure for locally advanced, unresectable, stage III non-small cell lung cancer in adults whose tumours express programmed death-ligand 1 on ≥ 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation therapy